John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.